Complete response for advanced liver cancer during sorafenib therapy: Case Report

BMC Gastroenterology

Volumn 11, Issue , 2011, Pages

  Sacco, Rodolfo ^a,b   Bargellini, Irene ^a   Gianluigi, Giannelli ^c   Bertini, Marco ^a   Bozzi, Elena ^a   Altomare, Emanuele ^b   Battaglia, Valentina ^a   Romano, Antonio ^a   Bertoni, Michele ^a   Capria, Alfonso ^a   Bresci, Giampaolo ^a   Bartolozzi, Carlo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; GELATINASE B; SORAFENIB; UREA; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CASE REPORT; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GALLSTONE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN THROMBOSIS; SPLENOMEGALY; LIVER TUMOR; METABOLISM; REMISSION; TREATMENT OUTCOME;

AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PYRIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 78651395593     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-11-4     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
2. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small Hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699. 10.1056/NEJM199603143341104, 8594428.
3. Bismuth H, Majno PE, Adam R. Liver transplantation for Hepatocellular carcinoma. Semin Liver Dis 1999, 19:311-322. 10.1055/s-2007-1007120, 10518310.
4. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for Hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086. 10.1053/jhep.2001.23561, 11343235.
5. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 2004, 40:1474-1484. 10.1016/j.ejca.2004.02.027, 15196530.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-90. 10.1056/NEJMoa0708857, 18650514.
7. Cheng A, Kang Y, Chen C, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008, 26:215.
8. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nat Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.
9. So BJ, Bekaii-Saab T, Bloomston MA, et al. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 2008, 1:18. 10.1186/1756-8722-1-18, 2575202, 18928548.
10. Yeganeh M, Finn RS, Saaba S. Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib. Amer Jour Transplant 2009, 9(12):2851-4.
11. Del Poggio P, Mattiello M, Gilardoni L, et al. The mysterious case of spontaneous disappearance of hepatocellular carcinoma. Dig Liver Dis 2009, 41:21-25.
12. Kojima H, Tanigawa N, Kariya S, et al. A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. Radiat Med 2006, 24:139-142. 10.1007/BF02493281, 16715676.
13. Eisen T, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008, 100:1454-63. 10.1093/jnci/djn319, 2567417, 18840822.
14. Porta C, et al. Efficacy and safety of sorafenib in elderly patients: results from a large open-label, non-comparative phase III study in European patients with advanced RCC (EU-ARCCS). Ann Oncol 2008, 19(suppl 8):viii193.
15. Dutcher Janice P, Tannir N, Bellmunt J. Bernard Escudier Experience with sorafenib and the elderly patient. Medical Oncology 2009,
16. Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, Gasbarrini A. portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol 2009, 104(7):1852-4. 10.1038/ajg.2009.140, 19574982.
17. Kim YG, Eun JR, Kim TN, et al. Pathological Complete Remission of advanced Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis by Hepatic Arterial Infusion Chemotherapy Gut and Liver. 2010, 4(2):266-269. 2886937, 20559534.
18. Li Q, Xu B, Fu L, Hao XS. Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res 2006, 25(3):403-9.
19. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, Liao M, Chen Z, Zhang Y. Overexpression of EphA2, MMP-9 and MVD-CD34 in HCC: implication for tumor progression and prognosis Yang et al. Hep Res 2009, 39(12):1169-77.
20. Shi GM, Ke AW, Zhou J, et al. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of HCC. Hepatology 2010, 52(1):183-96).
21. Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M. Expression of matrix metalloproteinase-9 in predicting prognosis of HCC after liver transplantation. Liver transplantation 2010, 16(5):621-30.
22. Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, Hayashi N. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on HCC cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010, 51(4):1264-73).
23. Mazzocca A, Giannelli G, Antonaci S. Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?. Biochimica et Biophysica Acta 1806, 74-81. (2010).
24. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
25. The AASLD guidelines 2010. , http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf